(January 2, 2020, 5:31 PM EST) -- MINNEAPOLIS — Plaintiffs in a class action suit alleging that a number of defendants breached their fiduciary duties by increasing the cost of the EpiPen prescription maintain in a Dec. 16 motion filed in Minnesota federal court that the certification of four classes is appropriate because the classes are ascertainable and the commonality and typicality requirements have been met (In re: EpiPen ERISA Litigation, No. 17-1884, D. Minn.)....